Skip to main content
Premium Trial:

Request an Annual Quote

Luminex, One Lambda Renew Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex said after the close of the market Tuesday that it has renewed its 10-year strategic partnership with One Lambda.

The alliance, which began in 2000, is focused on developing platforms and technologies for human leukocyte antigen typing and antibody screening for the organ transplantation market. One Lamda has developed a range of HLA tests based on Luminex's xMAP technology.

According to a Luminex statement, One Lambda sells products that can detect up to 500 HLA specificities in a single test and are sold in more than 80 countries worldwide.

Financial and other terms of the agreement were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.